PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33380272-5 2021 In this study, we investigated the effects of cervical vagotomy and the alpha7nAChR agonist pnu282987 on CD4+ T cell differentiation in a murine myocarditis model (BALB/c) infected with coxsackievirus B3 (CVB3). PNU-282987 92-101 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 72-83 32502508-0 2020 PNU282987 alleviates Abeta-induced anxiety and depressive-like behaviors through upregulation of alpha7nAChR by ERK-serotonin receptors pathway. PNU-282987 0-9 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 97-108 32502508-8 2020 Treatment with alpha7nAChR agonist PNU282987 or ERK inhibitor U0126 reversed Abeta-induced 5-HT1A and 5-HT2C receptor changes. PNU-282987 35-44 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 15-26 34299169-7 2021 However, treatment with PNU 282987, a selective alpha7 nicotinic receptor agonist, restored VAChT-KDHOM mice"s ability to increase alpha7 nicotinic receptor levels in response to LPS-induced acute lung injury and reduced lung inflammation. PNU-282987 24-34 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 48-73 34299169-7 2021 However, treatment with PNU 282987, a selective alpha7 nicotinic receptor agonist, restored VAChT-KDHOM mice"s ability to increase alpha7 nicotinic receptor levels in response to LPS-induced acute lung injury and reduced lung inflammation. PNU-282987 24-34 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 131-156 35293666-8 2022 This action of GTS-21 was reproduced by alpha7nAChR agonist PNU-282987, was enhanced by sitagliptin, was counteracted by Exendin(9-39), and was absent in alpha7nAChR and GLP-1R KO mice. PNU-282987 60-70 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 40-51 35351863-9 2022 In an IMQ-induced murine psoriasis model, alpha7nAChR agonist PNU-282987 treatment alleviated psoriasis-like inflammation by down-regulating the expression of multiple types of pro-inflammatory mediators and normalized keratinocyte proliferation and differentiation, whereas alpha7nAChR antagonist treatment exacerbated its effect. PNU-282987 62-72 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 275-286 35351863-9 2022 In an IMQ-induced murine psoriasis model, alpha7nAChR agonist PNU-282987 treatment alleviated psoriasis-like inflammation by down-regulating the expression of multiple types of pro-inflammatory mediators and normalized keratinocyte proliferation and differentiation, whereas alpha7nAChR antagonist treatment exacerbated its effect. PNU-282987 62-72 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 42-53 32980459-18 2021 Pharmacological activation of alpha7nAChR with PNU-282987 attenuated BCAA-induced injury in primary murine cardiomyocytes. PNU-282987 47-57 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 30-41 33995108-8 2021 PNU282987, an alpha7nAChR agonist, protected against OGD/R-induced neuronal injury, enhanced autophagy, and promoted autophagy flux. PNU-282987 0-9 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 14-25 33916910-3 2021 For this, BALB/c mice were injected intraperitoneally with LPS (0.33 mg/kg) and treated with the alpha7 nAChR agonist PNU282987, using different administration protocols. PNU-282987 118-127 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 97-109 33916910-5 2021 Peripheral (intraperitoneal) co-administration of the alpha7 nAChR agonist PNU282987 with LPS, attenuated body weight loss and sickness behavior associated with LPS challenge in adult mice, and reduced microglial activation with suppression of IL-1beta and TNFalpha mRNA levels. PNU-282987 75-84 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 54-66 33598912-9 2021 Administration of CHRNA7 agonist PNU-282987 attenuated pathological and inflammatory end points in a mouse model of chronic obstructive pulmonary disease (COPD). PNU-282987 33-43 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 18-24 34007230-6 2021 Then, 104 CD-1 mice were exposed to CIH for 4 weeks and randomly divided into four groups: CIH4W (control), with dimethyl sulfoxide (DMSO) (sham), with alpha7nAChR-specific agonist PNU-282987 (PNU), and with alpha7nAChR-specific inhibitor methyllycaconitine and PNU-282987 (MLA+PNU). PNU-282987 181-191 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 152-163 32619677-0 2020 Effects of VAChT reduction and alpha7nAChR stimulation by PNU-282987 in lung inflammation in a model of chronic allergic airway inflammation. PNU-282987 58-68 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 31-42 32705242-0 2020 Combined administration of SHP2 inhibitor SHP099 and the alpha7nAChR agonist PNU282987 protect mice against DSS-induced colitis. PNU-282987 77-86 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 57-68 32705242-3 2020 The present study aimed to evaluate the protective effects of PNU282987 and SHP099, which are a selective agonist of alpha7nAChR and an SHP2 inhibitor, respectively, in dextran sulfate sodium (DSS)-induced colitis in mice. PNU-282987 62-71 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 117-128 28732106-3 2017 To investigate the effect of the specific alpha7nAChR agonist, PNU282987, on cardiac remodelling induced by isoproterenol (ISO 60 mg/kg per day) in mice, the cardiomyocyte cross-sectional area (CSA) and collagen volume fraction were evaluated by hematoxylin and eosin (HE) and Masson staining, respectively. PNU-282987 63-72 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 42-53 29128415-11 2018 In addition, by using the alpha7nAChR agonist PNU282987, the p38 phosphorylation level decreases, rescues the biochemical changes which are tightly associated with Abeta-induced apoptosis, such as Bcl2/Bax level, cytochrome c (Cyt c) release. PNU-282987 46-55 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 26-37 31905173-6 2020 Collectively, the activation of alpha7 nAChR by PNU-282987 attenuated the toxic effect of Abeta in vivo and in vitro, which including reduced deposition of Abeta in the hippocampus, maintained synaptic morphology by partially reversing the expression levels of synaptic-associated proteins, activation of the Ca2+ signaling pathway, and improvement of the cognitive abilities of APP/PS1_DT mice. PNU-282987 48-58 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 32-44 30934054-9 2019 A selective alpha7-nAChR agonist, PNU282987, was applied by a puff and responses were recorded. PNU-282987 34-43 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 12-24 28279662-8 2017 Our results demonstrate the PPARalpha antagonist GW6471 blocks actions of the alpha7 nAChR agonist PNU282987 on nicotine reward in an unbiased CPP test in male ICR adult mice. PNU-282987 99-108 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 78-90 28941191-6 2017 PNU282987 also significantly inhibited the activation of NLRP3 inflammasome and thus decreased the production of IL-1beta and IL-18 both in lipopolysaccharide (LPS)/ATP-stimulated BV2 microglia in vitro and spinal cord from EAE mice in vivo, while inverse effects were observed in alpha7nAChR knockout mice. PNU-282987 0-9 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 281-292 28559895-9 2017 Activating alpha7nAChR with PNU282987 ameliorates EAE severity and spinal inflammatory infiltration in EAE mice. PNU-282987 28-37 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 11-22 27065867-7 2016 Involvement of alpha7nAChR was verified with methyllycaconitine (selective alpha7nAChR antagonist) and PNU282987 (selective alpha7nAChR agonist), or in alpha7nAChR knockout mice. PNU-282987 103-112 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 15-26 28315314-6 2017 In addition, nicotine and PNU282987 (alpha7-nAChR agonist) accelerated the growth of the cholangiocarcinoma tumors in our xenograft mouse model and increased fibrosis, proliferation of the tumor cells, and phosphorylation of extracellular-regulated kinase activation. PNU-282987 26-35 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 37-49 26650489-3 2016 The aim of this study was to investigate the accumulation of AGEs in the wounds and determine whether PNU282987, an alpha7nAChR agonist, can improve wound repair by inhibiting AGE-mediated TNF-alpha production in a streptozotocin (STZ)-induced diabetic mouse model. PNU-282987 102-111 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 116-127 26202362-10 2015 The alpha7 nAChR agonist PNU282987 was found to have an effect similar to that of ACh. PNU-282987 25-34 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-16 24811002-7 2014 In contrast, PNU282987, an alpha7 nicotinic receptor agonist, comparably salvaged skeletal muscle, which was affected by HLI. PNU-282987 13-22 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 27-52 25381636-4 2015 When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect. PNU-282987 67-77 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 79-91 22580739-8 2012 On the other hand, intravenous injection of the combined anisodamine and neostigmine, or the selective alpha7 nAChR agonist PNU282987 exerted similar anti-shock effects in dogs with hemorrhagic shock. PNU-282987 124-133 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 103-115 23311871-4 2013 Activation of alpha7 nAChR by PNU282987, after OGD, reduced cell death, reactive oxygen species production, and tumor necrosis factor release. PNU-282987 30-39 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 14-26